Clinical Trials Logo

Clinical Trial Summary

Patients enrolled from each center according to confirmed criteria specified in cooperative scheme are recieved induction and consolidation chemotherapy with microtransplantation . Observe the remission rate and 2-year disease-free survival (DFS) and overall survival(OS) rate.


Clinical Trial Description

Microtransplantation, which combines chemotherapy with adoptive infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC). Data from more than 70 elderly AML patients who received microtransplantation in Beijing showed that the remission rate and 2-year disease-free survival (DFS) reach 75-82% and 32-39% respectively, and microchimerisms (donor cells<1%) were detected without GVHD. The results have been clinically validated in several other centers in China, United States and Australia. In this study, azacytidine, decitabine, BCL / 2 inhibitor and other drugs combined with micro transplantation were used in elderly AML in order to improve the curative effect. Patients enrolled from each center according to confirmed criteria specified in cooperative scheme are recieved induction and consolidation chemotherapy with microtransplantation . Observe the remission rate and 2-year disease-free survival (DFS) and overall survival(OS) rate. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05262465
Study type Interventional
Source The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Contact yajing huang
Phone +8615811031508
Email yajing_huang@163.com
Status Recruiting
Phase N/A
Start date July 1, 2020
Completion date July 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT01146223 - Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia N/A
Completed NCT01295710 - Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Phase 3
Completed NCT01807091 - Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome N/A
Recruiting NCT03114670 - Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT Phase 1
Recruiting NCT05429632 - Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT Phase 3
Active, not recruiting NCT03226418 - Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia Phase 2
Recruiting NCT06329999 - A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML N/A
Completed NCT01484015 - Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia Phase 1
Completed NCT01041443 - 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Phase 1
Not yet recruiting NCT03283228 - Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia N/A
Completed NCT01251575 - Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Phase 2
Recruiting NCT06045819 - Relation Between Venetoclax Plasma Concentration and Remission in Adults With Acute Myeloid Leukemia (PREDICLAX)
Withdrawn NCT00101140 - Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission Phase 2